Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.05
MDSO's Cash to Debt is ranked lower than
54% of the 1618 Companies
in the Global Software - Application industry.

( Industry Median: 25.64 vs. MDSO: 1.05 )
MDSO' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 1.05

Equity to Asset 0.39
MDSO's Equity to Asset is ranked lower than
53% of the 1589 Companies
in the Global Software - Application industry.

( Industry Median: 0.60 vs. MDSO: 0.39 )
MDSO' s 10-Year Equity to Asset Range
Min: -1.75   Max: 0.63
Current: 0.39

-1.75
0.63
Interest Coverage 4.03
MDSO's Interest Coverage is ranked lower than
61% of the 1077 Companies
in the Global Software - Application industry.

( Industry Median: 403.68 vs. MDSO: 4.03 )
MDSO' s 10-Year Interest Coverage Range
Min: 4.03   Max: 9999.99
Current: 4.03

4.03
9999.99
F-Score: 6
Z-Score: 5.43
M-Score: -2.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.63
MDSO's Operating margin (%) is ranked higher than
77% of the 1604 Companies
in the Global Software - Application industry.

( Industry Median: 5.48 vs. MDSO: 8.63 )
MDSO' s 10-Year Operating margin (%) Range
Min: -36.17   Max: 14
Current: 8.63

-36.17
14
Net-margin (%) 6.02
MDSO's Net-margin (%) is ranked higher than
75% of the 1602 Companies
in the Global Software - Application industry.

( Industry Median: 3.67 vs. MDSO: 6.02 )
MDSO' s 10-Year Net-margin (%) Range
Min: -52.41   Max: 21.36
Current: 6.02

-52.41
21.36
ROE (%) 7.38
MDSO's ROE (%) is ranked higher than
70% of the 1564 Companies
in the Global Software - Application industry.

( Industry Median: 6.77 vs. MDSO: 7.38 )
MDSO' s 10-Year ROE (%) Range
Min: 7.38   Max: 44.63
Current: 7.38

7.38
44.63
ROA (%) 2.91
MDSO's ROA (%) is ranked higher than
64% of the 1616 Companies
in the Global Software - Application industry.

( Industry Median: 3.63 vs. MDSO: 2.91 )
MDSO' s 10-Year ROA (%) Range
Min: -53.2   Max: 20.75
Current: 2.91

-53.2
20.75
ROC (Joel Greenblatt) (%) 57.94
MDSO's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1600 Companies
in the Global Software - Application industry.

( Industry Median: 30.96 vs. MDSO: 57.94 )
MDSO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.03   Max: 266.31
Current: 57.94

-162.03
266.31
Revenue Growth (%) 14.00
MDSO's Revenue Growth (%) is ranked higher than
83% of the 1208 Companies
in the Global Software - Application industry.

( Industry Median: 6.30 vs. MDSO: 14.00 )
MDSO' s 10-Year Revenue Growth (%) Range
Min: -21.7   Max: 14
Current: 14

-21.7
14
EBITDA Growth (%) -5.60
MDSO's EBITDA Growth (%) is ranked higher than
60% of the 951 Companies
in the Global Software - Application industry.

( Industry Median: 7.70 vs. MDSO: -5.60 )
MDSO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 14.7
Current: -5.6

0
14.7
» MDSO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MDSO Guru Trades in Q1 2013

Chuck Royce 20,000 sh (New)
Tom Russo 81 sh (New)
Jim Simons 85,547 sh (+43.16%)
Steven Cohen Sold Out
» More
Q2 2013

MDSO Guru Trades in Q2 2013

Chuck Royce 20,000 sh (unchged)
Tom Russo Sold Out
Jim Simons 22,847 sh (-73.29%)
» More
Q3 2013

MDSO Guru Trades in Q3 2013

Steven Cohen 89,762 sh (New)
Mariko Gordon 3,640 sh (New)
Chuck Royce 20,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2013

MDSO Guru Trades in Q4 2013

Columbia Wanger 443,000 sh (New)
Jim Simons 60,094 sh (New)
Ron Baron 121,000 sh (New)
Chuck Royce 41,700 sh (+4.25%)
Steven Cohen Sold Out
Mariko Gordon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-12-31 New Buy0.03%$43.03 - $61.755 $ 51.95-6%121000
Mariko Gordon 2013-12-31 Sold Out 0.02%$43.03 - $61.755 $ 51.95-6%0
Mariko Gordon 2013-09-30 New Buy0.02%$36.86 - $50.41 $ 51.9518%3640
Joel Greenblatt 2012-12-31 Sold Out 0.04%$18.69 - $21.43 $ 51.95161%0
Joel Greenblatt 2012-06-30 Reduce -51.69%0.04%$12.28 - $16.34 $ 51.95278%16667
Joel Greenblatt 2012-03-31 Reduce -27.73%0.04%$9.31 - $13.83 $ 51.95403%34499
Joel Greenblatt 2011-09-30 Add 310.24%0.09%$7.27 - $12.24 $ 51.95460%45007
Lee Ainslie 2011-06-30 Sold Out 0.13%$10.7 - $13.06 $ 51.95335%0
Joel Greenblatt 2011-06-30 New Buy0.04%$10.7 - $13.06 $ 51.95335%10971
Lee Ainslie 2011-03-31 Reduce -44.59%0.1%$11.49 - $13.56 $ 51.95309%485479
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 165.00
MDSO's P/E(ttm) is ranked lower than
73% of the 1119 Companies
in the Global Software - Application industry.

( Industry Median: 23.20 vs. MDSO: 165.00 )
MDSO' s 10-Year P/E(ttm) Range
Min: 11.44   Max: 206.32
Current: 165

11.44
206.32
P/B 11.90
MDSO's P/B is ranked lower than
76% of the 1504 Companies
in the Global Software - Application industry.

( Industry Median: 2.45 vs. MDSO: 11.90 )
MDSO' s 10-Year P/B Range
Min: 2.26   Max: 15.4
Current: 11.9

2.26
15.4
P/S 10.20
MDSO's P/S is ranked lower than
85% of the 1650 Companies
in the Global Software - Application industry.

( Industry Median: 1.98 vs. MDSO: 10.20 )
MDSO' s 10-Year P/S Range
Min: 1.31   Max: 12.72
Current: 10.2

1.31
12.72
PFCF 71.90
MDSO's PFCF is ranked lower than
69% of the 874 Companies
in the Global Software - Application industry.

( Industry Median: 19.50 vs. MDSO: 71.90 )
MDSO' s 10-Year PFCF Range
Min: 12.91   Max: 179.68
Current: 71.9

12.91
179.68
EV-to-EBIT 111.10
MDSO's EV-to-EBIT is ranked lower than
76% of the 1278 Companies
in the Global Software - Application industry.

( Industry Median: 17.39 vs. MDSO: 111.10 )
MDSO' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 388.2
Current: 111.1

8.8
388.2
PEG 35.10
MDSO's PEG is ranked lower than
75% of the 601 Companies
in the Global Software - Application industry.

( Industry Median: 1.98 vs. MDSO: 35.10 )
MDSO' s 10-Year PEG Range
Min: 7.36   Max: 35.1
Current: 35.1

7.36
35.1
Shiller P/E 516.60
MDSO's Shiller P/E is ranked lower than
77% of the 616 Companies
in the Global Software - Application industry.

( Industry Median: 29.33 vs. MDSO: 516.60 )
MDSO' s 10-Year Shiller P/E Range
Min: 479.3   Max: 6000
Current: 516.6

479.3
6000

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.30
MDSO's Price/Tangible Book is ranked lower than
78% of the 1245 Companies
in the Global Software - Application industry.

( Industry Median: 4.00 vs. MDSO: 13.30 )
MDSO' s 10-Year Price/Tangible Book Range
Min: 3.16   Max: 30.04
Current: 13.3

3.16
30.04
Price/DCF (Projected) 8.70
MDSO's Price/DCF (Projected) is ranked lower than
76% of the 753 Companies
in the Global Software - Application industry.

( Industry Median: 1.50 vs. MDSO: 8.70 )
MDSO' s 10-Year Price/DCF (Projected) Range
Min: 4.85   Max: 10.1
Current: 8.7

4.85
10.1
Price/Median PS Value 3.00
MDSO's Price/Median PS Value is ranked lower than
79% of the 1516 Companies
in the Global Software - Application industry.

( Industry Median: 1.10 vs. MDSO: 3.00 )
MDSO' s 10-Year Price/Median PS Value Range
Min: 0.68   Max: 3.53
Current: 3

0.68
3.53
Price/Peter Lynch Fair Value 7.90
MDSO's Price/Peter Lynch Fair Value is ranked lower than
82% of the 365 Companies
in the Global Software - Application industry.

( Industry Median: 1.50 vs. MDSO: 7.90 )
MDSO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 9.22   Max: 9.22
Current: 7.9

Price/Graham Number 9.90
MDSO's Price/Graham Number is ranked lower than
84% of the 911 Companies
in the Global Software - Application industry.

( Industry Median: 2.20 vs. MDSO: 9.90 )
MDSO' s 10-Year Price/Graham Number Range
Min: 0.98   Max: 11.55
Current: 9.9

0.98
11.55
Earnings Yield (Greenblatt) 0.90
MDSO's Earnings Yield (Greenblatt) is ranked lower than
68% of the 1324 Companies
in the Global Software - Application industry.

( Industry Median: 5.40 vs. MDSO: 0.90 )
MDSO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 11.3
Current: 0.9

0.3
11.3
Forward Rate of Return (Yacktman) 20.95
MDSO's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 1007 Companies
in the Global Software - Application industry.

( Industry Median: 5.32 vs. MDSO: 20.95 )
MDSO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.5   Max: 21
Current: 20.95

0.5
21

Business Description

Industry: Application Software » Software - Application
Compare: » details
Traded in other countries:2M9.Germany
Medidata Solutions, Inc., was organized as a New York corporation in June 1999 and reincorporated in the State of Delaware in May 2000. The Company provides cloud-based solutions for life sciences that enhance the efficiency of its customers' clinical development processes from concept to conclusion, optimizing their research and development investments. Its solutions allow customers to increase the value of their development programs by more efficiently and effectively designing, planning, and managing key aspects of the clinical trial process, including study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding, clinical business analytics, and data flow and interoperability among multiple trial applications. Medidata Rave is a comprehensive solution that integrates electronic data capture, or EDC, with a clinical data management system, or CDMS, in a single solution that replaces traditional paper-based methods of capturing and managing clinical data. Medidata Rave offers a robust, flexible platform enabling sponsors to manage increasingly complex trials. Additional Rave solutions provide efficiencies in other areas of clinical data management, replacing separate activities with integrated, risk-minimizing, resource-saving solutions. Medidata CTMS is a clinical trial management system that offers robust, easy-to-use trial monitoring, administration, and tracking tools. Medidata Insights provides clinical business analytics for more informed development decisions and improved resource allocation, leading to increased operational effectiveness. Medidata Designer, a clinical study and protocol design tool, enables customers to design trial protocols more effectively and automatically configure Medidata Rave and other downstream systems, shortening the planning and set-up phase of the trial process. Medidata Grants Manager enables customers to increase the efficiency of trial budgeting and investigator contracting as well as improve compliance. Medidata CRO Contractor facilitates CRO outsourcing, budgeting and contract negotiation. Medidata Balance is a randomization development and execution application used for randomization and trial supply management, or RTSM, addressing not only the management of the randomization and supplies function, but also the design and implementation of the study. The Company markets and sells its application services through a direct sales force and through relationships with CROs and other strategic partners. The Company competes with firms including Oracle, Perceptive Informatics and other offering products that competes with one or more of its solutions. The use of Company's software products, services and hosted solutions by customers engaged in clinical trials must be done in a manner that is compliant with a complex array of Un

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide